Epiminder
Melbourne, Australia· Est.
Epiminder delivers FDA‑authorised implantable continuous EEG monitoring to transform care for drug‑resistant epilepsy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Epiminder delivers FDA‑authorised implantable continuous EEG monitoring to transform care for drug‑resistant epilepsy.
NeurologyEpilepsy
Technology Platform
Implantable continuous EEG monitoring (iCEM) system that records multi‑year brain activity via a sub‑cutaneous electrode array with wireless telemetry and cloud‑based analytics.
Opportunities
Expansion into US and EU markets, leveraging remote monitoring data for AI‑driven seizure analytics, and extending the platform to other neurological disorders.
Risk Factors
Regulatory and reimbursement challenges, manufacturing scale‑up, and competition from established neuro‑diagnostic and neuro‑stimulation devices.
Competitive Landscape
Competitors include NeuroPace and Medtronic's neuro‑stimulation systems; Epiminder differentiates with long‑term, continuous EEG capture and FDA Breakthrough designation for diagnostic monitoring.